Nasdaq · Biotech stocks database
XTLB — XTL Biopharmaceuticals Ltd. ☆
XTLB (XTL Biopharmaceuticals Ltd.) stock: $1.55, $3.8M market cap, $0.4M cash, $3.6M EV, $0.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We have prepared our consolidated financial statements in United States, or US, dollars and in accordance with International Financial Reporting Standards, or IFRS. All references herein to “dollars” or “$” are to US dollars, and all references to “Shekels” or “NIS” are to New Israeli Shekels.
Source: 20-F FY2025 via SEC EDGAR
Balance sheet
Cash $0.4M Debt $0.1M Net cash $0.2M Enterprise value $3.6M Basic shares 2.5M shares Fully diluted shares 0.1M shares Fully diluted market cap $0.2M Cash per share $0.15 Quarterly burn $0.1M Cash runway 2.6 quarters
Cash figures as of 2024-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading XTLB daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.